Also in this playlist...
This transcript is automatically generated
So recent study says -- the improvement of new drugs has actually decreased over the last few decades this would obviously have a big impact on patients seeking care.
Could also have a big impact on pharmaceutical and Biotech company's president CEO of Acorda Therapeutics doctor Ron Cohen joins us with his thoughts.
-- at the point of diminishing returns in drug research just to hear that actually.
I mean I got to believe there's people sitting in -- home.
It's too upset to hear that what does that mean you're not gonna keep discovering new drugs.
But it's very upsetting if you believe the headlines but fortunately the headlines are not true.
-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- So there's an unprecedented amount of research going into new cures and the good news is that the science that we understand our understanding of the biology and how to develop cures for various diseases has never been greater.
So it's my -- were actually on the threshold now of yet another wave of incredible innovation in pharmaceutical discovery that's gonna help a lot of people.
And if you look if you look back.
The last twenty years alone -- produced unprecedented.
Innovation for diseases like multiple sclerosis and rheumatoid arthritis.
And schizophrenia and depression and cancer.
-- I think that it's a very bright future of the one problem.
Is that it is getting more and more expensive.
To do that.
Right let's talk about that because it's expensive in two different ways one you're saying that this this -- -- have increased and that's a good thing.
In general it's a good thing because you want to have drugs that are proved to be safe and effective so those standards help to do that.
There are some in the industry and I would join them who would argue that.
The standards have in some cases become too strict and need more balance.
Between safety and effectiveness so that you are not just cutting off a drug because there's some safety issue within.
But rather balancing out.
What is the patient getting out of it and what -- the patient willing.
To accept in terms of safety in turn in in return for what they're getting.
Because you're saying you were saying before we came on that it could cost upwards of a billion dollars to get a drug correct.
But that is also because we are such a litigious society isn't it and not everyone will -- because my name now fell off of -- to the medication.
Well I think it certainly that's part of it and legal settlements.
We've we've various people who -- including the government by the way which is a big problem now.
Those are problem but I -- an even bigger issue is simply that.
It cost a lot to develop drugs and there's no real way around that if you want to have the regulatory standards that we have.
On the other hand.
We should be doing everything we can to take every impediment away.
So that we don't make it harder than it already is to develop drug.
Which brings us to our conversation the last time you hear about the FDA the FDA basically cutting back.
Because of the sequester cut -- less people at the FDA to actually administer all these tests to bring drugs to market.
Right so big irony is that a fair amount of the funding for the FDA actually comes from the biopharmaceutical industry companies like like -- -- -- -- -- and we pay a fee for them to do their work and that's we we willingly except that in order to have a good regulatory process.
Under the sequester.
Even the fees that we pay from the private sector into the FDA those part of those were sequestered.
Congress fortunately has a bill right now I hope it goes through that's trying to restore that money so the FDA has -- available space they're trying to reverse everything they did are you feeling the effects of the -- yet.
It's too soon to feel it but there is no question that the whole industry will be feeling it over the next year or two if something's not done to reverse that and would be a total impediment to what you're saying that we are on the brink of a bunch and you -- drugs -- -- correct.
Doctor Colin thanks for coming on my pleasure trips effects of getting updates.
Filter by section